Skip to main content

Mosseri Marlio Charles's Form 4 filing

Nuvectis Pharma, Inc. (NVCT) · filed May 9, 2025

Accession no.
0001104659-25-046882
Filed
May 9, 2025
Trade date
May 6-8, 2025
Filing delay
3 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 8 non-derivative transactions. Open-market purchases total $235.6K. It was filed 3 days after the trade, past the 2-business-day deadline.

This filing was later replaced by the amendment 0001104659-25-047089 (May 12, 2025). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mosseri Marlio CharlesCIK 000180638410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 6, 2025Common StockPPurchaseAcquired+2,340$8.40+$19,6562,886,461Indirect
May 6, 2025Common StockPPurchaseAcquired+10,104$8.64+$87,298.562,896,565Indirect
May 7, 2025Common StockPPurchaseAcquired+2,703$8.40+$22,705.22,899,268Indirect
May 7, 2025Common StockPPurchaseAcquired+9,614$8.64+$83,064.962,908,882Indirect
May 8, 2025Common StockPPurchaseAcquired+50$8.65+$432.52,908,932Indirect
May 8, 2025Common StockPPurchaseAcquired+100$8.65+$8652,909,032Indirect
May 8, 2025Common StockPPurchaseAcquired+100$8.65+$8652,909,132Indirect
May 8, 2025Common StockPPurchaseAcquired+2,400$8.65+$20,7602,911,532Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)